Literature DB >> 8193094

Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation.

L A Norris1, B L Sheppard, G Burke, J Bonnar.   

Abstract

OBJECTIVE: To study platelet function in normotensive and hypertensive intrauterine growth retardation (IUGR).
DESIGN: ADP and collagen induced whole blood platelet aggregation, beta-thromboglobulin release and platelet count were measured in the IUGR groups at a mean gestational age of 36 weeks (28-40), and at 1, 24, 48 h and six weeks post delivery. The normal pregnancy group were studied serially at 12, 20, 28, 32 and 36 weeks of gestation and at 1, 24, 48 h and six weeks post delivery.
SETTING: Trinity College Medical School, St. James's Hospital, Dublin.
SUBJECTS: Twenty-nine women with a fetus with diagnosed IUGR were recruited for the study. Of these, 15 were normotensive throughout their pregnancy and the remaining 14 pregnancies were complicated by both hypertension and proteinuria. Twenty healthy primigravida acted as controls.
RESULTS: In the hypertensive IUGR group, levels of collagen and ADP induced aggregation were almost 50% lower before delivery than in normal pregnancy. Platelet count in the hypertensive group was decreased by 30% compared with normal pregnancy. Levels of beta-thromboglobulin were 40 to 50% higher in both the normotensive and hypertensive IUGR groups compared with normal pregnancy. Unlike the hypertensive IUGR group, the normotensive IUGR group showed similar levels of platelet count and ADP and collagen induced aggregation to those found at 36 weeks of normal pregnancy. In the early puerperium of hypertensive pregnancies, the platelet parameters measured returned gradually to normal. The normotensive IUGR group had increased levels of ADP induced aggregation in the first 24 to 48 h post delivery. The platelet count in the normotensive but not the hypertensive group correlated with birthweight.
CONCLUSIONS: Normotensive and hypertensive IUGR are accompanied by platelet activation. In normotensive IUGR, this activation appears to be confined to the uteroplacental circulation. In hypertensive IUGR, the results suggest that platelet activation also extends into the peripheral circulation resulting in a reduced platelet responsiveness and a lower platelet count. Release of vasoactive amines from activated platelets in the peripheral circulation may be responsible for the clinical syndrome of hypertension and proteinuria present in pregnancies complicated by pre-eclampsia and IUGR but absent in normotensive IUGR.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193094     DOI: 10.1111/j.1471-0528.1994.tb13111.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

1.  First-trimester prediction of preeclampsia in nulliparous women at low risk.

Authors:  Leslie Myatt; Rebecca G Clifton; James M Roberts; Catherine Y Spong; John C Hauth; Michael W Varner; John M Thorp; Brian M Mercer; Alan M Peaceman; Susan M Ramin; Marshall W Carpenter; Jay D Iams; Anthony Sciscione; Margaret Harper; Jorge E Tolosa; George Saade; Yoram Sorokin; Garland D Anderson
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

2.  Platelet Indices and CXCL12 Levels in Patients with Intrauterine Growth Restriction.

Authors:  Shole Shahgheibi; Roya Mardani; Erfan Babaei; Parastoo Mardani; Masomeh Rezaie; Fariba Farhadifar; Daem Roshani; Mobin Naqshbandi; Ali Jalili
Journal:  Int J Womens Health       Date:  2020-04-21

3.  Platelets in Fetal Growth Restriction: Role of Reactive Oxygen Species, Oxygen Metabolism, and Aggregation.

Authors:  Joanna Nowaczyk; Barbara Poniedziałek; Piotr Rzymski; Dominika Sikora; Mariola Ropacka-Lesiak
Journal:  Cells       Date:  2022-02-18       Impact factor: 6.600

4.  Platelet Changes in Pregnancies with Severe Early Fetal Intrauterine Growth Restriction.

Authors:  Anca Marina Ciobanu; Anca Maria Panaitescu; Nicolae Gica; Ana Maria Scutelnicu; Alexandra Bouariu; Mihaela Roxana Popescu
Journal:  Medicina (Kaunas)       Date:  2021-12-12       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.